title: [Low-dose cytosine-arabinoside (Ara-C) therapy for chronic myeloid leukemia].
abstract: The effects of low doses of cytosine-arabinoside (Ara-C) were studied in 17 patients with chronic myeloid leukemia: chronic, resistant to IFN and hydroxyurea therapy (including 4 cases of advanced chronic disease)--7, and tumor progression--10. Hematologic effect was recorded in 7 chronic patients tolerant to hydroxyurea and alpha-interferon therapy. Among 10 cases of tumor progression, chronic stage II was observed in 3, stabilization (tumor progression short of blastic crisis)--5, and without effect--1. Low-dose Ara-C treatment was considered effective in 15 (88%) out of 17 patients.
authors.affiliation: Russian Research Institute of Hematology and Transfusiology, St. Petersburg.
authors.forename: K M
authors.initials: KM
authors.lastname: Abdulkadyrov
authors.forename: O A
authors.initials: OA
authors.lastname: Rukavitsyn
authors.forename: V I
authors.initials: VI
authors.lastname: Udal'eva
authors.forename: T A
authors.initials: TA
authors.lastname: Kornilova
authors.forename: I S
authors.initials: IS
authors.lastname: Martynkevich
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003561:Cytarabine / Q000008:administration & dosage*; D018450:Disease Progression; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine